STERIS (STE) Company Report

Total as-reported revenue grew 10%, with constant currency organic revenue up 9% (210 bps price contribution).
Gross margin rose 60 bps to 44.3%, and EBIT margin increased 90 bps to 23.1%, driven by price, productivity, and operating‐expense leverage.
Adjusted EPS from continuing operations was $2.47, up 15%, and net income reached $244.5 million.
Free cash flow for the first half was $527.7 million; total debt was $1.9 billion with gross-to-EBITDA of ~1.2×.
FY 2026 guidance raised to 8–9% as-reported revenue growth (7–8% constant currency organic), EPS of $10.15–$10.30, EBIT margin expansion of 10–20 bps, and free cash flow of $850 million.

Nov 6, 2025, 2:00 PM

Transcript

STERIS reports Q2 Fiscal 2026 results and raises full-year guidance

STE

Earnings

Guidance Update

Revenue grew 10% year-over-year (constant-currency organic growth 9%), with gross margin up 60 bps to 44.3% and EBIT margin up 90 bps to 23.1% in Q2 FY 2026.
Healthcare revenue rose on a constant-currency organic basis by 9%, led by service (+13%), consumables (+10%) and capital equipment (+4%; backlog > $400 million); AST services grew 13% (AST EBIT margin 45.3%); Life Sciences revenue grew 12%, driven by capital equipment (+39%; backlog $114 million).
Free cash flow in H1 FY 2026 was $527.7 million, debt stood at $1.9 billion with gross/EBITDA ~1.2x at quarter-end.
Full-year guidance raised: as-reported revenue growth 8%–9%, constant-currency organic revenue growth 7%–8%, adjusted EPS $10.15–$10.30, and free cash flow $850 million.

Nov 6, 2025, 2:00 PM

Transcript

STERIS reports Q2 fiscal 2026 results

STE

Earnings

Guidance Update

In Q2, revenue grew 10%, with 9% constant currency organic growth; gross margin improved 60 bps to 44.3%, EBIT margin rose 90 bps to 23.1%, net income was $244.5 M, and adjusted EPS was $2.47 (+15%).
Healthcare segment organic revenue +9% (service +13%, consumables +10%, capital equipment +4%, backlog >$400 M); AST organic +7% (services +13%, EBIT margin 45.3% +250 bps); Life Sciences organic +12% (capital equipment +39%, margin –70 bps).
Raised fiscal 2026 outlook: as-reported revenue +8–9%, constant currency organic +7–8%, EPS $10.15–$10.30, EBIT margin +10–20 bps, effective tax ~24%, free cash flow $850 M, and CapEx ~$375 M.
First-half free cash flow reached $527.7 M, ending debt was $1.9 B (gross debt/EBITDA ~1.2×).

Nov 6, 2025, 2:00 PM

Transcript

STERIS announces Q2 FY 2026 results

STE

Earnings

Guidance Update

Reported $1.5 billion in total revenue from continuing operations, a 10% increase year-over-year, with 9% constant currency organic growth.
As-reported EPS from continuing operations rose to $1.94, while adjusted EPS climbed to $2.47, both up versus Q2 FY 2025.
All three segments drove growth: Healthcare revenue up 9% to $1,033.8 million; Applied Sterilization Technologies up 10% to $281.5 million; Life Sciences up 13% to $145.0 million.
Company upgraded its full-year fiscal 2026 outlook for constant currency organic revenue, EPS and free cash flow.

Nov 5, 2025, 9:41 PM

8-K

STERIS announces fiscal 2026 second quarter results

STE

Earnings

Guidance Update

STERIS posted a 10% year-over-year rise in Q2 revenue to $1.5 billion, with 9% constant currency organic growth.
As reported EPS from continuing operations climbed to $1.94, while adjusted EPS reached $2.47, versus $1.51 and $2.14 a year ago, respectively.
Q2 segment performance: Healthcare revenue up 9% to $1,033.8 million; AST revenue up 10% to $281.5 million; Life Sciences revenue up 13% to $145.0 million.
First-half net cash from operations was $707.8 million; free cash flow totaled $527.7 million, driven by earnings growth and working capital improvements.
Fiscal 2026 guidance raised: constant currency organic revenue growth now 7–8%, adjusted EPS outlook $10.15–$10.30, and free cash flow target $850 million.

Nov 5, 2025, 9:30 PM

Press Release

STERIS reports Q1 2026 results and guidance update

STE

Earnings

Guidance Update

CFO Change

Revenue grew 9% (8% constant currency organic) with gross margin of 45.3%, EBIT margin of 22.8%, and adjusted EPS of $2.34 (+15%); free cash flow was $327 M in Q1
Segment performance: Healthcare organic revenue +8%; AST organic +10% (services +12%) with AST EBIT margin up 150 bps to 48.6%; Life Sciences organic +4% and backlog +50% to $111 M
Full-year guidance: As-reported revenue growth raised to 8–9% (organic CC unchanged at 6–7%), EPS unchanged at $9.90–$10.15, and free cash flow increased to $820 M; tariff headwinds offset by ~200 bps of FX tailwind
CFO transition: Mike Tokich to become special financial advisor, with Karen succeeding him as CFO
Dividend: 20th consecutive annual increase, raised 10% to $0.63 per quarter

Aug 7, 2025, 4:30 PM

STERIS plc Reports Q4 2025 Performance

STE

Earnings

Guidance Update

Share Buyback

Q4 2025 results: Reported total revenue growth of 4% and organic revenue increase of 6%, with gross margins rising to 44.3% and adjusted EPS from continuing operations at $2.74, up 40% year-over-year.
Full-year performance & outlook: Achieved 6% revenue growth and 12% earnings growth for fiscal 2025, with guidance for fiscal 2026 projecting as reported revenue growth of 6%-7% and inclusion of $30 million in tariff costs.
Capital and share repurchase activities: Recorded capital expenditures of $370 million, free cash flow of a record $787 million, and repurchased approximately $200 million of shares during fiscal 2025.

May 15, 2025, 1:01 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for STERIS.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Daniel Carestio say about margins?What are STERIS's strategic priorities?How is STERIS positioned vs competitors?How did STERIS do last quarter?

Let Fintool AI Agent track STERIS's earnings for you

Get instant analysis when filings drop